2Seventy Bio Inc (TSVT)

May 7, 2025, 4:05 PM EDT - 26 days ago

2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb

Apr 16, 2025, 5:16 PM EDT - 6 weeks ago

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

BMY

Mar 25, 2025, 4:05 PM EDT - 2 months ago

2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 3:31 PM EDT - 2 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.

BMY

Mar 11, 2025, 10:17 AM EDT - 2 months ago

Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal

BMY

Mar 11, 2025, 8:55 AM EDT - 2 months ago

Top 3 Health Care Stocks That May Keep You Up At Night In Q1

SNY VRTX

Mar 11, 2025, 7:17 AM EDT - 2 months ago

Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million

BMY

Mar 10, 2025, 10:17 PM EDT - 2 months ago

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

BMY

Feb 25, 2025, 7:00 AM EST - 3 months ago

2seventy bio to Participate in the 2025 TD Cowen Healthcare Conference

Feb 6, 2025, 7:03 AM EST - 4 months ago

2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results

Jan 13, 2025, 6:10 PM EST - 4 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Nov 12, 2024, 11:16 AM EST - 7 months ago

2seventy bio, Inc. (TSVT) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:00 AM EST - 7 months ago

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

Nov 4, 2024, 4:01 PM EST - 7 months ago

2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference

Oct 11, 2024, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against 2seventy bio, Inc. (TSVT) And Encourages Shareholders to Reach Out

Oct 10, 2024, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against 2seventy bio, Inc. (TSVT) and Encourages Shareholders to Learn More About the Investigation

Oct 9, 2024, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating 2seventy bio, Inc. (TSVT) And Encourages Investors to Connect

Oct 8, 2024, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages 2seventy bio, Inc. (TSVT) Stockholders to Inquire about Securities Investigation

Oct 7, 2024, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against 2seventy bio, Inc. (TSVT) And Encourages Stockholders to Reach Out

Oct 6, 2024, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating 2seventy bio, Inc. (TSVT) And Encourages Stockholders to Connect

Sep 25, 2024, 11:56 AM EDT - 8 months ago

Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability

BMY

Sep 25, 2024, 6:51 AM EDT - 8 months ago

2seventy Bio stops enrolling patients in blood cancer therapy study

Sep 25, 2024, 6:00 AM EDT - 8 months ago

2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance

Aug 29, 2024, 7:00 AM EDT - 9 months ago

2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference

Aug 11, 2024, 4:52 AM EDT - 10 months ago

2seventy bio, Inc. (TSVT) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 7:00 AM EDT - 10 months ago

2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress

Aug 5, 2024, 7:00 AM EDT - 10 months ago

2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 9, 2024, 7:06 AM EDT - 11 months ago

2seventy bio's Abecma: Compelling Investment In Multiple Myeloma Despite Competition

Jun 26, 2024, 4:11 PM EDT - 1 year ago

2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million

May 23, 2024, 7:00 AM EDT - 1 year ago

2seventy bio to Participate in Upcoming Investor Conferences

May 8, 2024, 3:15 PM EDT - 1 year ago

2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:00 AM EDT - 1 year ago

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress

May 3, 2024, 7:00 AM EDT - 1 year ago

2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024

Apr 3, 2024, 9:34 AM EDT - 1 year ago

2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround

Apr 1, 2024, 7:30 AM EDT - 1 year ago

2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron

Mar 20, 2024, 5:04 PM EDT - 1 year ago

2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors